These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 26492896)

  • 1. Brazilian Valuation of EQ-5D-3L Health States: Results from a Saturation Study.
    Santos M; Cintra MA; Monteiro AL; Santos B; Gusmão-Filho F; Andrade MV; Noronha K; Cruz LN; Camey S; Tura B; Kind P
    Med Decis Making; 2016 Feb; 36(2):253-63. PubMed ID: 26492896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Logical Inconsistencies in 3 Preference Elicitation Methods for EQ-5D Health States: A Study in the Brazilian Population.
    Andrade MV; Noronha K; Kind P; Reis Cde B; de Carvalho LR
    Med Decis Making; 2016 Feb; 36(2):242-52. PubMed ID: 26289747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What matters most? Evidence-based findings of health dimensions affecting the societal preferences for EQ-5D health states.
    Andrade MV; Noronha KV; Maia AC; Kind P
    Cad Saude Publica; 2013 Nov; 29 Suppl 1():S59-72. PubMed ID: 25402251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EQ-5D Brazilian population norms.
    Santos M; Monteiro AL; Santos B
    Health Qual Life Outcomes; 2021 Jun; 19(1):162. PubMed ID: 34112207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Scuffham PA
    Health Qual Life Outcomes; 2013 Sep; 11():149. PubMed ID: 24070162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
    Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
    Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
    Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chinese time trade-off values for EQ-5D health states.
    Liu GG; Wu H; Li M; Gao C; Luo N
    Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EQ-5D-3L derived population norms for health related quality of life in Sri Lanka.
    Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
    PLoS One; 2014; 9(11):e108434. PubMed ID: 25365171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L.
    Wong EL; Cheung AW; Wong AY; Xu RH; Ramos-Goñi JM; Rivero-Arias O
    Value Health; 2019 Aug; 22(8):916-924. PubMed ID: 31426933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
    Stevens K; Brazier J; Rowen D
    Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
    Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
    Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.